Pemafibrate Add-on theRapy in Type 2 diabetes with MASLD uNdErgoing SGLT2 inhibitoR-Juntendo Shizuoka:PARTNER-JS

Pemafibrate Add-on theRapy in Type 2 diabetes with MASLD uNdErgoing SGLT2 inhibitoR-Juntendo Shizuoka:PARTNER-JS - PARTNER-JS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056024

Enrollment

100

Registered

2024-11-14

Start date

2024-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes dyslipidemia MASLD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age>18yo 2. Subjects with T2D undergoing tofogliflozin treatment 3. TG>150mg/dL(fasting), TG>175mg/dL(casual) 4. MASLD 5. Agreement

Exclusion criteria

Exclusion criteria: Contraindication for pemafibrate

Design outcomes

Primary

Measure	Time frame
ALT	—

Secondary

Measure	Time frame
BMI, AST, TG	—

Countries

Japan

Contacts

Public ContactTakashi Nomiyama

Juntendo University Shizuoka Hospital Department of Diabetes, Endocrinology and Metabolism

nomiyama@juntendo.ac.jp0559483111

Outcome results